SMAD1-AS2

Across TCGA pan-cancer cohorts, SMAD1-AS2 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated SMAD1-AS2 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher SMAD1-AS2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SMAD1-AS2 expression acts as an unfavorable survival marker, although some lineages such as BRCA and STAD show a favorable association.

CHOL, THCA, and READ are the cancer types where SMAD1-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Quartile	All	0.057	0.716	<.001	48	view →
THCA	OS	Quartile	All	0.941	0.991	.001	36	view →
READ	DFS	Tertile	III,IV	0.179	0.767	<.001	36	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
UCEC	OS	Tertile	All	0.880	0.939	.004	34	view →
MESO	OS	Tertile	II,III,IV	0.267	0.625	.008	27	view →
ACC	DFS	Tertile	IV	0.039	0.407	.004	27	view →
BLCA	OS	Tertile	All	0.555	0.711	.028	18	view →
BRCA	DFS	Tertile	III,IV	0.943	0.833	.007	15	view →
LGG	OS	Median	All	0.336	0.577	.001	15	view →
STAD	OS	Tertile	II,III,IV	0.597	0.404	.024	11	view →
THYM	OS	Tertile	II,III,IV	0.549	0.961	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

SMAD1-AS2–CHOL (OS)

Open the CHOL breakdown →